Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 277

The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

Open access
Javid, Hossein, Oryani, Mahsa Akbari, Rezagholinejad, Nastaran, Esparham, Ali, Tajaldini, Mahboubeh, Karimi‐Shahri, Mehdi·2024·Cancer Medicine

Abstract

RGD peptide can be found in cell adhesion and signaling proteins, such as fibronectin, vitronectin, and fibrinogen. RGD peptides' principal function is to facilitate cell adhesion by interacting with integrin receptors on the cell surface. They have been intensively researched for use in biotechnology and medicine, including incorporation into biomaterials, conjugation to medicinal molecules or nanoparticles, and labeling with imaging agents. RGD peptides can be utilized to specifically target cancer cells and the tumor vasculature by engaging with these integrins, improving drug delivery efficiency and minimizing adverse effects on healthy tissues. RGD‐functionalized drug carriers are a viable option for cancer therapy as this focused approach has demonstrated promise in the future. Writing a review on the RGD peptide can significantly influence how drugs are developed in the future by improving our understanding of the peptide, finding knowledge gaps, fostering innovation, and making drug design easier.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cam4.6800

Cites

198 of 198 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 198 references

Cited by

See all 277

Metadata

Authors
Javid, H., Oryani, M. A., Rezagholinejad, N., Esparham, A., Tajaldini, M., & Karimi‐Shahri, M.
Venue
Cancer Medicine
Publisher
Wiley
Published
2024-01
Volume
13
Issue
2
Pages
e6800-e6800
ISSN
2045-7634 (ISSN-L)
OpenAlex
W4391436075
Cited by
277
References
198
FWCI
72.99
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions. https://app.cochat.ai/papers/10.1002/cam4.6800
The paper
Javid, H., Oryani, M. A., Rezagholinejad, N., Esparham, A., Tajaldini, M., & Karimi‐Shahri, M. (2024). RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions. Cancer Medicine. https://doi.org/10.1002/cam4.6800

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.